导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.74% | 2731/4773 |
| 近一周 | -1.28% | 385/5462 |
| 近一月 | -2.19% | 1197/5421 |
| 近一季 | -5.70% | 1897/5209 |
| 近半年 | -2.97% | 2082/4920 |
| 近一年 | 0.26% | 2605/4366 |
| 近两年 | 37.50% | 1995/2954 |
| 近三年 | 24.18% | 1315/2253 |
| 成立以来 | 242.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.47% 1812/4961 |
8.02% 2636/5312 |
- - |
- - |
| 2025 | 13.50% 2639/4813 |
0.65% 1801/3635 |
2.82% 1329/4076 |
7.28% 3461/4524 |
2.23% 1035/4813 |
| 2024 | 16.85% 752/3463 |
2.61% 744/2808 |
-0.96% 877/3014 |
16.25% 1499/3129 |
-1.08% 1583/3463 |
| 2023 | -2.98% 619/2656 |
5.23% 812/2280 |
-2.12% 561/2385 |
-0.74% 442/2515 |
-5.09% 1255/2655 |
| 2022 | -13.48% 331/2207 |
-10.68% 410/1919 |
3.99% 1070/2016 |
-10.89% 459/2113 |
4.53% 540/2208 |
| 2021 | -2.53% 857/1822 |
-1.13% 435/1255 |
1.95% 1025/1330 |
-8.53% 1136/1466 |
5.72% 272/1822 |
| 2020 | 34.94% 430/1250 |
-7.99% 583/1028 |
14.05% 573/1067 |
12.77% 365/1164 |
14.03% 308/1184 |
| 2019 | 44.47% 170/1092 |
25.68% 448/754 |
0.22% 187/804 |
4.95% 172/850 |
9.30% 236/918 |
| 2018 | -23.04% 267/834 |
- - |
- - |
- - |
-13.38% 530/691 |
| 2017 | 42.89% 19/714 |
- - |
- - |
- - |
- - |
| 2016 | 0.41% 104/605 |
- - |
- - |
- - |
- - |
| 2015 | 14.18% 145/575 |
- - |
- - |
- - |
- - |
| 2014 | 26.27% 178/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商央视财经50指数A VS. 长安沪深300非周期A(740101) |